Novel, high accuracy models for hepatocellular carcinoma prediction based on longitudinal data and cell-free DNA signatures
Rong Fan(Kunming Institute of Botany), Jinlin Hou(Southern Medical University), Junqi Niu(Jilin University), Yanyan Yu(Nanchang University), Qing Xie(Shanghai Jiao Tong University), Jian Sun(Nanfang Hospital), Dan Zheng, Huiying Rao(Peking University), Yanhang Gao(Jilin University), Guoqing Jiang(Yangzhou University), Xiaoguang Dou(China Medical University), Xieer Liang(Nanfang Hospital), Jie Xia(Fudan University), Hongbo Gao(Houston Methodist), Yan-Long Yu(Chifeng University), Lei Chen(Zhuzhou Central Hospital), Yali Liu(Nanjing University of Chinese Medicine), Xiaolong Liu(Guilin University of Technology), Yongfeng Yang(Capital Medical University), Hongyang Wang(Second Military Medical University), Jingfeng Liu(Fujian Medical University), Qi Xia(Peking University), Yang Song(Nanjing Medical University), Lin Wu(Berry Oncology (China)), Chunying Wang(Hebei Science and Technology Department), Aimin Sun(Zhengzhou University), Dong‐Ying Xie(Sun Yat-sen University), Pujun Gao(Jilin University), Honglian Bai(First People's Hospital of Foshan), Xin Hao(Ministry of Education of the People's Republic of China), Hong Ma(Beijing Friendship Hospital), Yun-Song Qian(University of Chinese Academy of Sciences), Yongfang Jiang(Central South University), Zhengmao Li(Peking University), Siru Zhao(Nanfang Hospital), Jian Bai(Berry Oncology (China)), Chuanxin Wang(Jilin University), Xiaotang Fan(Army Medical University), Jianping Xie(Central South University), Jia Shang(European Foundation for the Study of Chronic Liver Failure)
Cited by 42
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer
|Nature Communications|2018|1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934